ImmunoPrecise Antibodies Q1 Sales $4.24M Beat $3.94M Estimate; As Of July 31, 2023, IPA Held $6.8M Of Cash
Portfolio Pulse from Benzinga Newsdesk
ImmunoPrecise Antibodies (NASDAQ:IPA) reported Q1 sales of $4.24 million, beating the analyst consensus estimate of $3.94 million by 7.70 percent. This represents a 16.41 percent increase over sales of $3.65 million the same period last year. As of July 31, 2023, IPA held $6.8M of cash.
September 14, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ImmunoPrecise Antibodies reported better than expected Q1 sales, which could positively impact its stock price.
ImmunoPrecise Antibodies reported Q1 sales that beat analyst estimates by 7.7%. This positive financial performance, coupled with a YoY sales increase of 16.41%, could lead to increased investor confidence and a potential rise in the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100